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Abstract
Objectives: This randomized clinical trial was designed to investigate whether inchinkoto has a
hepatoprotective effect on postoperative outcome after major hepatectomy.
Methods: Sixty-one patients scheduled for major hepatectomy were randomly assigned to one of two
groups in which preoperative inchinkoto was (inchinkoto group, n = 30) or was not (non-inchinkoto group,
n = 31) administered. Inchinkoto was administered for at least 7 days before surgery. The primary endpoint
was the incidence of post-hepatectomy liver damage. The expression of nuclear factor E2-related factor
2 (Nrf2) and other oxygen stress-related markers in the liver were also determined.
Results: There was no significant difference in clinical characteristics between the inchinkoto and
non-inchinkoto groups. Serum levels in liver function tests and incidences of post-hepatectomy liver
failure did not differ significantly between the two groups. However, there was a significantly higher
induction of antioxidant factors in the liver, such as Nrf2 protein and heme oxygenase-1 mRNA, after
hepatectomy in the inchinkoto group than in the non-inchinkoto group.
Conclusions: The preoperative administration of inchinkoto did not have a significant impact on the
overall outcome of major hepatectomy. However, inchinkoto induced the expression of Nrf2 during
hepatectomy and may have exerted an antioxidative effect on the liver.
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Introduction
During major hepatectomy, intermittent clamping of the
hepatoduodenal ligament (the Pringle manoeuvre) is commonly
performed to reduce intraoperative blood loss. However, this pro-
cedure may lead to hepatic ischaemia–reperfusion injury and
cause post-hepatectomy liver failure. Although numerous animal
and human studies have been performed to determine how
ischaemia–reperfusion-induced liver injury might be prevented1–3
or to improve liver function after major hepatectomy,4,5 no defini-
tive strategy has been established for use in a real clinical setting.
In Japan, China and some eastern countries, several herbal
medicines have been used in clinical settings. Among them,
inchinkoto, which is derived from plants and contains abundant
bioactive materials, is one of the most commonly used
hepatoprotective agents.6,7 Several studies have shown that
inchinkoto exerts choleretic effects by enhancing expression of
multidrug resistance-associated protein 2 (Mrp2/MRP2).8,9 Addi-
tionally, in an animal study, inchinkoto and its ingredients have
been shown to exert antioxidative actions in rat liver.10 Moreover,
the present authors have recently demonstrated that preoperative
administration of inchinkoto provides beneficial effects by attenu-
ating inflammatory responses and oxidative stress in the rat liver
following ischaemia–reperfusion and subsequent hepatectomy.11
Based on these observations, it can be hypothesized that preop-
erative inchinkoto administration may exert hepatoprotective
effects in patients submitted to major hepatectomy. However, data
on the effects of inchinkoto in human major hepatectomy are still
insufficient.
Nuclear factor E2-related factor 2 (Nrf2) is a key regulator of
numerous detoxifying and antioxidant genes.12 In a previous study
using an animal model, Nrf2 and Nrf2-induced antioxidant
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factors, such as hemeoxygenase-1 (HO-1), were upregulated in the
livers of rats that had been treated with inchinkoto.10 However,
these events have never been demonstrated in the human liver.
This paper reports a randomized controlled trial designed to
determine whether preoperative inchinkoto treatment has a pro-
tective effect in the livers of patients submitted to major hepate-
ctomy.
Materials and methods
From June 2010 to January 2012, patients who were scheduled to
undergo major hepatectomy were randomly assigned to groups in
which preoperative inchinkoto was or was not administered. No
placebo drug was used in this study because it is extremely diffi-
cult to make a drug with taste and properties similar to those of
inchinkoto. Major hepatectomies in this study included hepatec-
tomy with resection of at least three Couinaud segments. Patients
who refused to participate in the study were not included. Further
exclusion criteria denied the participation of patients who
required the administration of other choleretic drugs (such as
ursodeoxycholic acid) for severe jaundice, patients who had
received preoperative chemotherapy, and patients in whom the
remnant liver volume was expected to be <20% before portal vein
embolization (PVE). This study was neither single- nor double-
blinded for the treatment with inchinkoto. However, observers of
the clinical outcome and the results of the biological analysis of
liver samples were blinded to treatment group. The primary end-
point was the severity of postoperative liver damage, which was
primarily evaluated according to levels of serum aspartate
aminotransferase (AST) and alanine aminotransferase (ALT). The
secondary endpoint was the expression of antioxidant factors in
the liver. To predict the number of patients required for statistical
validity (two-sided), the study design was based on a previous
animal study conducted by this group.11 In the animal study, levels
of AST and ALT after 15 min of liver ischaemia and 70% hepate-
ctomy were approximately 500 IU/l in the group without
inchinkoto treatment and 300 IU/l in the group with inchinkoto
treatment. The standard deviation was approximately 200 IU/l in
both groups. The α-value was set at 0.05 and the β-value at 0.2,
which yielded a power of 80%. Calculations showed that at least
25 patients were required in each arm of this study. The study
protocol was approved by Nagoya University Ethics Committee
[University Hospital Medical Information Network (000003690;
http://www.umin.ac.jp/]. This randomized clinical trial is
reported according to the guidelines laid out in the CONSORT
(consolidated standards of reporting trials) statement.13
Preoperative administration of inchinkoto
Inchinkoto (TJ-135; Tsumura & Co., Tokyo, Japan) was adminis-
tered orally at a dose of 7.5 g/day from the date of participation
until 1 day prior to surgery. Inchinkoto was administered for at
least 7 days.
Preoperative patient management
The plasma disappearance rate (PDR) of indocyanine green
(ICG) and computed tomography (CT) volumetry were routinely
assessed to evaluate the functional reserve of the future liver
remnant. In general, an ICG PDR in the future liver remnant
(ICG-F) value, which is calculated by multiplying the ICG PDR by
the proportion of the liver represented by the future liver remnant,
of ≥0.05 is considered a safety cut-off for major hepatectomy.14 At
the study institution, when the volume of liver to be resected
exceeded 60% or when the ICG-F value was <0.05, PVE was
performed to increase the volume of the future liver remnant.15,16
Monitoring of clinical data and postoperative
complications
Detailed daily clinical records were kept for all patients. Serum
levels of bilirubin concentration (T-Bil), AST, ALT, lactate
dehydrogenase (LDH) and prothrombin time international nor-
malized ratio (PT-INR) were measured preoperatively, soon after
the operation, and on postoperative days (PoDs) 1, 3, 5 and 7.
Post-hepatectomy liver failure and post-hepatectomy bile leakage
were defined based on the criteria of the International Study
Group of Liver Surgery (ISGLS).17,18 More specifically, post-
hepatectomy liver failure was defined according to a PT-INR value
of >1.5 and serum T-Bil of >2 mg/dl on or after PoD 5. Post-
hepatectomy liver failure was graded according to severity as
follows: grade A represents post-hepatectomy liver failure result-
ing in abnormal parameters but requiring no change in the clini-
cal management of the patient; grade B represents post-
hepatectomy liver failure that requires some deviation from
regular clinical management but is manageable without invasive
treatment, and grade C represents post-hepatectomy liver failure
that results in some deviation from regular clinical management
and requires invasive treatment.
Postoperative infectious complications including pneumonia,
surgical site infection and bacteraemia confirmed by culture were
also recorded for up to 30 days after the procedure. The diagnosis
of pneumonia required radiological evidence of consolidation
with leukocytosis. Surgical site infections included superficial or
deep incisional infections and organ space infections occurring
within 30 days of the operation.19 Bacteraemia was diagnosed
when a blood culture grew an isolate of organisms without con-
tamination of skin flora. The severity of complications was clas-
sified according to the Clavien–Dindo system.20
Intraoperative liver biopsy
During the surgery, liver tissue specimens (approximately 5 mm2)
were sampled from the liver edge before any procedure was
carried out and after the hepatectomy had been completed. The
remnant liver lobe was used for sampling because it was not
affected by preoperative PVE. Specimens were divided into two
pieces. One piece was minced and snap-frozen in liquid nitrogen
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for Western blot analysis and real-time reverse transcriptase poly-
merase chain reaction (RT-PCR). The other piece was embedded
in paraffin for tissue evaluation.
Real-time RT-PCR
To validate the changes in gene expression in liver tissue speci-
mens, quantitative real-time RT-PCR analysis was performed
using a Prism 7300 sequence detection system (Applied
Biosystems, Inc., Foster City, CA, USA). Total RNA was isolated
from liver tissue using the RNeasy Mini Kit (Qiagen GmbH,
Hilden, Germany) according to the manufacturer’s protocol.
cDNA was generated from the total RNA samples using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Inc.). Each reaction was performed in a 20-μl mixture including
TaqMan universal PCR master mix according to the manufactu-
rer’s instructions (Applied Biosystems, Inc.). All samples were
tested in duplicate, and average values were used for quantifica-
tion. Analysis was performed using MxPro Version 2.00
(Stratagene, Inc., La Jolla, CA, USA) according to the manufactu-
rer’s instructions. The comparative cycle threshold method was
used to quantify gene expression. Data for one subject in the
non-inchinkoto group were considered as indicating one-fold
induction and other data were adjusted to that baseline. TaqMan
probes and primers for the genes of HO-1 (assay ID no.
Hs01110250_m1), superoxide dismutase (SOD) (assay ID no.
Hs00167309_m1) and glutathione synthetase (GSS) (assay
ID no. Hs00609286_m1) were purchased (Applied Biosystems,
Inc.). An 18s rRNA assay (ID no. Hs99999901_s1; Applied
Biosystems, Inc.) was used as the endogenous control.
Western blot analyses
Liver samples were homogenized in a Laemmli buffer. Protein
levels were determined using the RC-DC Assay Kit (Biorad
Laboratories, Inc., Hercules, CA, USA). A sample of 30 μg of liver
homogenate protein was used in electrophoresis on SDS-
polyacrylamide gels transferred to a polyvinylidene difluoride
membrane (Immobilon; EMD Millipore, Billerica, MA, USA).
Anti-Nrf2 antibodies (Santa Cruz Biotechnology, Inc., Dallas, TX,
USA) and horseradish peroxidase-conjugated secondary anti-
bodies (DAKO Denmark A/S, Glostrup, Denmark) were detected
with an enhanced chemiluminescence reagent (Amersham
Biosciences, Inc., Piscataway, NJ, USA) and exposed to X-ray film
(Fujifilm Corp., Tokyo, Japan).21 Band intensity was analysed
using Image Version 1.56 (National Institutes of Health, Bethesda,
MD, USA) and expression levels of Nrf2 protein were normalized
to a loading control (β-actin) in all samples.
Histological evaluation
For histological evaluation, tissues from all patients in each group
were examined. Liver samples were immediately fixed in neutral
buffered formalin and embedded in paraffin. Some sections were
subjected to immunohistochemistry to detect the expression of
Nrf2. The automated slide preparation system Discovery XT
(Ventana Medical Systems, Inc., Tucson, AZ, USA) was used for
immunohistochemistry. Before staining, paraffin sections were
heated at 65 °C for 15 min in a paraffin oven and blocked with 5%
non-fat milk. The staining procedure was carried out according to
the manufacturer’s protocol (Ventana Medical Systems, Inc.).
Anti-Nrf2 antibody (Abcam plc, Cambridge, UK) was diluted in
Discovery® Ab diluent (Ventana Medical Systems, Inc.).
Statistical analysis
Data were analysed using jmp for Windows Version 8.0 (SAS Insti-
tute, Inc., Cary, NC, USA). Results are presented as the mean ±
standard error (SE) or the median (range) for quantitative vari-
ables and as percentages for qualitative variables. The chi-squared
test was used for categorical variables, and the non-parametric
Wilcoxon rank sum test and parametric Student’s t-test were used
for continuous variables. The level of significance was set at a
P-value of <0.05.
Results
Patient flow
Of the 76 eligible patients, 73 consecutive patients were enrolled in
this study. Thirty-eight patients were randomized to the non-
inchinkoto group and 35 to the inchinkoto group. Twelve patients
were excluded because they underwent probe laparotomy for peri-
toneal dissemination, liver metastasis or distant nodal metastasis.
Therefore, 61 patients completed the trial (non-inchinkoto group,
n = 31; inchinkoto group, n = 30).
Baseline patient characteristics
There was no significant difference between the inchinkoto and
non-inchinkoto groups in gender, age or type of disease (Table 1).
Neither did incidences of comorbid illness, preoperative
cholangitis or biliary drainage procedures required differ signifi-
cantly between the two groups. Because the majority of the study
patients had biliary tract malignancies, obstructive jaundice was
observed in >40% and preoperative biliary drainage was required
in >70% of patients in both groups. There were no significant
differences between the inchinkoto and non-inchinkoto groups in
preoperative ICG retention at 15 min (R15), ICG PDR, ICG-F or
remnant liver volume. Portal vein embolization was performed in
over half of the patients in each group.
Procedures and intraoperative variables
The type of hepatectomy and the incidence of combined vascular
resection were similar across the two groups (Table 2). Operation
time, blood loss and total time of hepatic ischaemia were also
comparable between the two groups.
Postoperative outcomes
Serum levels of maximum T-Bil, AST and ALT, as well as
maximum PT-INR, did not differ significantly between the two
groups (Table 3). Overall, incidences of postoperative complica-
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tions and postoperative liver failure, as well as Clavien–Dindo
scores, were similar in both groups. There were no surgery-related
deaths in this study.
Induction of antioxidative factors during hepatectomy
The upregulation of antioxidant genes in response to
hepatic ischaemia–reperfusion has been shown to represent a
hepatoprotective mechanism in many animal studies.22,23 There-
fore, the present study was designed to compare expression levels
of antioxidant genes in the liver before and after hepatectomy in
patients treated and not treated with inchinkoto before surgery.
Despite similar levels of surgical invasion and total hepatic
ischaemia time between the two groups, the mean induction
levels of antioxidant genes, such as HO-1 and SOD, were higher
in the inchinkoto group than in the non-inchinkoto group
(Fig. 1a). The level of HO-1 mRNA was especially significantly
upregulated (more than 12-fold) after hepatectomy in the
inchinkoto group compared with that in the non-inchinkoto
group. The upregulation of Nrf2 protein, which is a key regula-
tor of antioxidant gene expression, after hepatectomy was also
significantly higher in the inchinkoto group than in the non-
inchinkoto group (Fig. 1b and c).
Immunohistochemistry for Nrf2
To confirm the presence of Nrf2 in the liver, immuno-
histochemistry was performed. Expression of Nrf2 protein was
greater in the nucleus after hepatectomy than before hepatectomy.
Moreover, this enhanced expression of Nrf2 was more prominent
in the inchinkoto group than in the non-inchinkoto group
(Fig. 1d). The average number of Nrf2-positive nuclei in high-
powered fields after hepatectomy was significantly higher in tissue
from the inchinkoto group than in that from the non-inchinkoto
group (Fig. 1e).
Table 1 Clinical characteristics of patients submitted to major hepatectomy with and without the administration of inchinkoto prior to surgery
Variable Non-inchinkoto
group (n = 31)
Inchinkoto
group (n = 30)
P-value
Gender, male/female, n 17/14 17/13 0.89
Age, years, mean ± SE 69 ± 9 67 ± 11 0.35
Disease, n 0.40
Cholangiocarcinoma 25 22
Hepatocellular carcinoma 3 4
Benign 2 2
Gallbladder carcinoma 1 1
Colorectal liver metastasis 0 1
Comorbid illness, n (%)
Diabetes mellitus 6 (19%) 4 (13%) 0.39
Hepatitis 3 (10%) 1 (3%) 0.32
Preoperative cholangitis, n (%) 6 (19%) 6 (20%) 0.95
Obstructive jaundice, n (%) 13 (42%) 12 (40%) 0.74
Preoperative biliary drainage, n (%) 0.72
PTBD 3 (10%) 5 (17%)
ENBD 20 (65%) 18 (60%)
No drainage 8 (25%) 7 (23%)
T-Bil, mg/dl, mean ± SE 0.7 ± 0.3 0.7 ± 0.2 0.73
AST, IU/l, mean ± SE 49 ± 63 45 ± 21 0.64
ALT, IU/l, mean ± SE 57 ± 55 60 ± 39 0.79
PT-INR, mean ± SE 1.03 ± 0.06 1.02 ± 0.07 0.48
ICG R15, %, mean ± SE 9.1 ± 4.6 8.9 ± 5.9 0.85
PDR ICG, mean ± SE 0.163 ± 0.031 0.172 ± 0.039 0.32
PDR ICG-F, mean ± SE 0.085 ± 0.025 0.092 ± 0.030 0.25
Remnant liver volume, cm3, mean ± SE 520 ± 228 546 ± 165 0.60
Portal vein embolization, n (%) 17 (55%) 19 (63%) 0.50
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ENBD, endoscopic nasobiliary drainage; ICG R15, indocyanine green retention rate
at 15 min; PDR ICG, plasma disappearance rate of indocyanine green; PDR ICG-F, PDR ICG of the future remnant; PTBD, percutaneous transhepatic
biliary drainage; PT-INR prothrombin time international normalized ratio; SE, standard error; T-Bil, bilirubin concentration.
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Table 2 Performed procedure and intraoperative variables in patients submitted to major hepatectomy with and without the administration
of inchinkoto prior to surgery
Variables Non-inchinkoto
group (n = 31)
Inchinkoto
group (n = 30)
P-value
Type of hepatectomy, n 0.69
Left hepatectomy (+PD) 9 (1) 8
Left trisectionectomy 8 8
Right hepatectomy (+PD) 9 (1) 7 (6)
Right trisectionectomy 3 1
Combined vascular resection, n (%) 0.82
Portal vein alone 5 (16%) 4 (13%)
Hepatic artery alone 2 (7%) 0
Portal vein + hepatic artery 3 (10%) 3 (10%)
Inferior vena cava 1 (3%) 0
Surgery
Time, min, mean ± SE 531 ± 109 553 ± 168 0.538
Blood loss, ml, mean ± SE 1503 ± 1802 1723 ± 1165 0.574
Total hepatic ischaemia time, min, mean ± SE 70 ± 28 74 ± 25 0.503
With any transfusion, n (%) 26 (84%) 29 (97%)
Autologous 22 (71%) 23 (77%) 0.61
Packed red blood cells 9 (29%) 8 (27%) 0.84
Fresh frozen plasma 5 (16%) 6 (20%) 0.48
Platelet concentrate 1 (3%) 0 0.51
PD, pancreatoduodenectomy; SE, standard error.
Table 3 Postoperative outcomes in patients submitted to major hepatectomy with and without the administration of inchinkoto prior to
surgery
Variables Non-inchinkoto
group (n = 31)
Inchinkoto
group (n = 30)
P-value
Postoperative laboratory tests, mean ± SE
Maximum T-Bil, mg/dl 3.2 ± 2.1 3.1 ± 1.6 0.84
Maximum AST, IU/l 645 ± 539 611 ± 469 0.79
Maximum ALT, IU/l 455 ± 342 498 ± 415 0.66
Maximum PT-INR 1.91 ± 0.78 1.78 ± 0.30 0.38
With any complications, n (%) 26 (84%) 22 (73%) 0.32
PHLF by ISGLS criteria, n (%) 0.40
None 11 (35%) 11 (37%)
Grade A 3 (10%) 7 (23%)
Grade B 14 (45%) 11 (37%)
Grade C 3 (10%) 1 (3%)
Complications by Clavien–Dindo grade, n (%) 0.13
Grade I 4 (13%) 9 (30%)
Grade II 11 (35%) 5 (17%)
Grade IIIa 16 (52%) 16 (53%)
Grade IIIb–V 0 0
Postoperative hospital stay, days, mean ± SE 30 ± 16 31 ± 20 0.82
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ISGLS, International Study Group of Liver Surgery; PHLF, post-hepatectomy liver
failure; PT-INR prothrombin time international normalized ratio; SE, standard error; T-Bil, bilirubin concentration.
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Subgroup analysis
The extent of hepatectomy varied among patients included in this
study (Table 2). Therefore, a subgroup analysis of data for patients
with ICG-F values of ≦0.08 (16 patients in the non-inchinkoto
group and 10 patients in the inchinkoto group) was performed.
Patients with an ICG-F value of ≦0.08 have a high risk for post-
operative liver failure as a result of small remnant liver function.
In this subgroup, although there was no difference in pre- and
intraoperative variables between the non-inchinkoto and
inchinkoto groups (data not shown). Levels of AST immediately
after the operation and on PoDs 1 and 3, levels of ALT immedi-
ately after the operation and on PoDs 1, 3 and 5, and levels of LDH
immediately after the operation were significantly lower in the
inchinkoto group than in the non-inchinkoto group (Fig. 2a–c).
Furthermore, the incidence of post-hepatectomy liver failure of
grades B and C was higher in the non-inchinkoto group (75%)
than in the inchinkoto group (50%).
Discussion
Although numerous experimental studies have shown
hepatoprotective effects of inchinkoto,24–26 few clinical studies
have evaluated its effects in humans.9,27,28 Previously, this group
reported that preoperative administration of inchinkoto provides
beneficial effects following ischaemia–reperfusion and subsequent
hepatectomy in rats.11 These results implied possible benefits of
inchinkoto administration in major hepatectomy in humans.
However, only one study by Kaiho et al. has tested the benefits of
inchinkoto in human hepatectomy.28 This clinical study included
various extents of hepatectomy, such as partial hepatectomy,
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Figure 1 Liver sample findings in patients submitted to major hepatectomy with or without the preoperative administration of inchinkoto. (a)
Expression levels of antioxidant genes HO-1, SOD and GSS assessed by polymerase chain reaction. (b) Representative Western blot images
for the expression of antioxidant protein Nrf2 and loading control protein β-actin in the liver before and after hepatectomy (Hx). (c) The
average ratio of Nrf2 protein expression after hepatectomy to that before hepatectomy in one individual. *P < 0.05 versus the non-inchinkoto
group. (d) Representative immunohistochemistry images for the expression of Nrf2 protein in the liver before and after hepatectomy (×400).
(e) The average number of Nrf2-positive nuclei in randomly selected high-powered fields in the liver after hepatectomy. Three random fields
were selected in each case. *P < 0.05 versus the non-inchinkoto group
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segmentectomy and lobectomy. The average resection rate was
26–29%, which was extremely low in comparison with that in the
present study (∼50%). Moreover, no study has demonstrated the
effects of inchinkoto pretreatment on expression of antioxidant
factors in the human liver. The present study was intended to
elucidate the effects of inchinkoto in the context of ‘major’ hepa-
tectomy, defined as the resection of at least three Couinaud
segments.
The analysis of data for all patients submitted to major hepa-
tectomy in the present series showed no significant difference
between the inchinkoto and non-inchinkoto groups in postopera-
tive outcomes, including liver function tests and incidences of
post-hepatectomy liver failure and other morbidities. Compared
with the well-controlled animal study,11 in which ischaemia–
reperfusion was induced in a 70% hepatectomy model, patient
characteristics, preoperative liver function and the degree of
operative invasion of major hepatectomy were variable in this
human study. The incidence of post-hepatectomy liver failure is
closely related to the volume and function of the remnant liver, the
two variables that represent the major determinants of the
adequacy of the future remnant liver after resection.14 In this
regard, the ICG-F value used in this study is a relevant indicator of
operative severity. Therefore, a subsequent subgroup analysis of
patients who had undergone more severe major hepatectomy as
indicated by low ICG-F values (≦0.08) was performed. Interest-
ingly, in this subgroup analysis, postoperative serum levels of AST,
ALT and LDH were found to be significantly lower in the
inchinkoto group than in the non-inchinkoto group, indicating
that inchinkoto exerts hepatoprotective effects in severe major
hepatectomy. The results were also consistent with those of the
previous report by Kaiho et al., which showed a significant reduc-
tion in serum total bilirubin levels after administration of
perioperative inchinkoto in patients submitted to hepatectomy of
>40% of liver volume.28
During major hepatectomy, repeated vascular occlusion and
release is necessary to minimize intraoperative blood loss.
However, this procedure leads to ischaemia–reperfusion-induced
liver injury. Excessive production of reactive oxygen species by
neutrophils and Kupffer cells in the liver is considered to be one of
the major mechanisms responsible for liver injury secondary to
ischaemia–reperfusion stress.29 Several previous animal studies
have shown that inchinkoto upregulates antioxidative factors10,11
and this mechanism may at least partially explain its
hepatoprotective effects against ischaemia–reperfusion stress.
However, no previous reports have demonstrated the antioxidative
action of inchinkoto in a human model. The present study dem-
onstrates for the first time that inchinkoto induces antioxidative
factors, such as Nrf2 and HO-1, in the human liver in response to
the stress of hepatectomy that accompanies repeated total vascular
occlusion and release. When the levels of expression of antioxidant
genes in the liver before and after hepatectomy were compared, the
expression of antioxidant genes such as HO-1 was found to be
highly upregulated and to a significantly higher degree in the
inchinkoto group than in the non-inchinkoto group (Fig. 1a). The
induction of Nrf2, a key regulator against antioxidative stress, in
the inchinkoto group was also significantly higher than that in
the non-inchinkoto group by Western blot analysis and
immunohistochemistry. It is speculated that the antioxidative
action enhanced by inchinkoto may partially explain the
hepatoprotective effects observed in severe major hepatectomy in
patients with ICG-F values of≦0.08, but a subgroup analysis in the
present study showed no significant difference between the non-
inchinkoto and inchinkoto groups in the expression of antioxidant
factors (data not shown). However, this analysis is likely to have
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Figure 2 Serum levels of (a) aspartate aminotransferase (AST), (b)
alanine aminotransferase (ALT) and (c) lactate dehydrogenase (LDH)
in the subgroup of patients with indocyanine green plasma clear-
ance in the future liver remnant values of≦0.08. *P < 0.05 versus the
non-inchinkoto group. Preoperative, 1 day before surgery; postop-
erative, immediately after surgery; PoD, postoperative day
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been underpowered because of the small numbers of patients in
each group (16 in the non-inchinkoto group and 10 in the
inchinkoto group). A large study in a patient series limited to those
undergoing more severe hepatectomy, with comparative character-
istics in terms of preoperative liver function and operative pro-
cedure, is required to test this hypothesis. Several previous animal
studies have demonstrated that genipin, a major ingredient of
inchinkoto, plays a pivotal role in the antioxidant effects of
inchinkoto.8,10,11 Although it is not technically possible to measure
the level of genipin in the blood with any technique currently
available, this should be monitored in the future.
In the overall study population, there was no significant differ-
ence in AST (645 IU/l versus 611 IU/l) and ALT (455 IU/l versus
498 IU/l) levels between the two groups. The evaluation of liver
damage by AST or ALT level may not have represented a suitable
primary endpoint because these factors are relatively unspecific
for liver damage. In a future study, another index that may more
accurately reflect postoperative liver damage following major
hepatectomy should be sought and used to evaluate whether there
is a benefit of inchinkoto administration. In the present study,
inchinkoto was administered only preoperatively, and postopera-
tive management in the inchinkoto and non-inchinkoto groups
was identical. If inchinkoto had been administered pre- and post-
operatively, its hepatoprotective effects may have been enhanced
and may have changed the postoperative course in the inchinkoto
group. In addition, the study was not double-blinded and thus
placebo effects cannot be excluded in the inchinkoto group. More-
over, the patients included in this study were heterogeneous in
terms of comorbid risk factors, preoperative management and
extent of surgery, although statistical analysis indicated that there
were no significant differences in these characteristics between the
two groups (Tables 1 and 2). This heterogeneity may have under-
powered this trial because the number of patients included in this
study was not sufficiently large. The manufacture of a high-quality
placebo drug to be used in a carefully controlled double-blinded
clinical trial in a large series of patients is necessary to determine
the usefulness of inchinkoto in major hepatectomy.
In conclusion, although the primary outcome did not differ
between the inchinkoto and non-inchinkoto groups, this
randomized clinical trial provides evidence that inchinkoto
strongly induces hepatic expression of Nrf2 and HO-1 after major
hepatectomy. Further investigations are required to elucidate the
benefits of inchinkoto in marginal major hepatectomy with
strictly defined remnant liver function.
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